GSK discloses CEO shareholding and GSK stock costs EUR 21.20

Published on 10/13/2026 at 10:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CEO Luke Miels acquired 3 shares at GBP 17.59 on October 8, 2026. GSK stock costs EUR 21.20 on October 13, 2026.

GSK disclosed that CEO Luke Miels acquired 3 ordinary shares through the Share Reward Plan on October 8, 2026.
GSK stock was at EUR 21.20 at Lang & Schwarz on October 13, 2026 at 10:20 a.m. CEST.
Second-quarter 2026 revenue reached GBP 8.41 billion, while core operating profit rose 7 percent to GBP 2.80 billion.
GSK is scheduled to report third-quarter 2026 results on October 28, 2026.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK (ISIN GB00BN7SWP63) disclosed that CEO Luke Miels acquired 3 ordinary shares at GBP 17.59 through its Share Reward Plan on October 8, 2026, in a filing published on October 12, 2026 by Reuters. GSK stock was at EUR 21.20 at Lang & Schwarz on October 13, 2026 at 10:20 a.m. CEST.

Three events shape the stock

On July 28, 2026, GSK reported second-quarter revenue of GBP 8.41 billion and core operating profit of GBP 2.80 billion, up 5 percent and 7 percent respectively from the comparable period, according to Drillr. The core operating margin was 33.30 percent, while reported operating profit was GBP 481.00 million after GBP 1.90 billion of impairments.

On September 15, 2026, Berenberg upgraded GSK from Hold to Buy and raised its target from GBP 20.00 to GBP 22.00, citing pipeline activity and business development, Sharecast reported. The target revision gives the analyst view a concrete valuation anchor, while the current euro quote remains a separate German-market reference.

What does the next report test

GSK's next scheduled report covers the quarter ended September 30, 2026, with the release and investor conference set for October 28, 2026, according to finanzen.net. Its consensus expects GBP 8.88 billion of revenue and GBP 0.505 earnings per share for that quarter, compared with GBP 8.55 billion and GBP 0.500 in the prior-year quarter.

That forecast places the next report between two competing signals: core operating profit grew 7 percent in the second quarter, while the reported result was reduced by GBP 1.90 billion of impairments. For investors, the September-quarter figures will show whether commercial growth can absorb acquisition and research costs.

Dates and market reference

GSK's October 12 filing is the latest dated corporate event in this review. The October 28 results date is the next major company milestone, while Wendy Becker's new directorship at Tesco takes effect on November 1, 2026, according to Reuters.

GSK's primary listing is on the London Stock Exchange, where the finance quote showed GBp 1,791.50 at 9:27 a.m. BST on October 13, 2026. The same listing's 52-week range was GBp 1,592.00 to GBp 2,282.00, providing a wider market frame for the EUR 21.20 Lang & Schwarz quote.

The further course of trading is shown by the continuously updated real-time quote of GSK stock.